Mǎrgulescu AD. Assessment of aortic valve disease - a clinician oriented review. World J Cardiol 2017; 9(6): 481-495 [PMID: 28706584 DOI: 10.4330/wjc.v9.i6.481]
Corresponding Author of This Article
Andrei D Mǎrgulescu, MD, PhD, Specialist in Cardiology and Internal Medicine, Assistant Professor, Department of Cardiology, University and Emergency Hospital, 169 Splaiul Independentei, Sector 5, Bucharest 050098, Romania. andrei_marg@yahoo.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jun 26, 2017; 9(6): 481-495 Published online Jun 26, 2017. doi: 10.4330/wjc.v9.i6.481
Table 1 Echocardiographic criteria for the definition of severe aortic stenosis: Advantages and disadvantages[18]
Criteria
Severe AS
Advantages
Disadvantages
Aortic surface area
≤ 1.0 cm2
Measures effective AVA. However, this may also constitute a disadvantage because it does not measure anatomical AVA
Very sensitive to measurement errors
Less flow-dependent compared with other measurements
Indexed AVA to body surface area
≤ 0.6 cm2/m2
Useful for extreme heights/weights
Very sensitive to measurement errors
Mean transaortic pressure gradient
≥ 40 mmHg
Flow-dependent
Requires correct alignment of Doppler signal with the flow direction
Peak transaortic flow velocity
≥ 4.0 m/s
Measures instantaneous velocity
Flow-dependent
Best predictor of adverse events
Requires correct alignment of Doppler signal with the flow direction
Ratio between peak transaortic flow velocity and peak LVOT velocity
≤ 1/4
Good reproducibility (compared with AVA calculation)
Limited data on prognostic utility
Table 2 Indication for aortic valve replacement according to European Society of Cardiology/European Association for Cardio-Thoracic Surgery and American Heart Association/American College of Cardiology guidelines[33,34]
Criteria
Level of recommendation
Differences between guidelines
ESC/EACTS
AHA/ACC
Severe AS with any symptoms clearly due to AS, based on history or unmasked by stress test
I
I
"High-gradient" in AHA/ACC guidelines
Asymptomatic severe AS with LVEF < 50%
I
I
Severe AS and another indication for surgery (CABG, thoracic aorta, another valve)
I
I
Asymptomatic severe AS where the systolic blood pressure does not increase by > 20 mmHg or drops compared with baseline during the treadmill test
IIa
IIa
AHA/ACC guidelines acknowledge the presence of fatigability during stress test as an indication for AVR
Moderate AS and another indication for surgery (CABG, thoracic aorta, another valve)
IIa
IIa
Low-flow/low-gradient/low-LVEF severe AS with proof of contractile reserve presence
IIa
IIa
Symptomatic low-flow/low-gradient/preserved LVEF severe AS after careful confirmation of severity
IIa
IIa
Truly asymptomatic severe AS (no symptoms during treadmill test, no risk criteria) with preserved LVEF if the surgical risk is deemed low and the following criteria are also satisfied: Very severe AS (maximal velocity ≥ 5.5 m/s); Severe valvular calcification and increased maximal velocity by ≥ 0.3 m/s per year
IIa
IIa for velocity ≥ 5 m/s (see text)
AHA/ACC guideline: Velocity ≥ 5 m/s or mean gradient ≥ 60 mmHg AND severe calcifications; velocity 4 to 4.9 m/s or mean gradient 40 to 59 mmHg AND severe valvular calcification AND stress test demonstrating reduced tolerance or drop in blood pressure
IIb for maximal velocity increase by ≥ 0.3 m/s per year
Truly asymptomatic severe AS (no symptoms during treadmill test, no risk criteria) with preserved LVEF if the surgical risk is deemed low and 1 or more of the following criteria are also satisfied: Severely increased BNP/Nt-ProBNP levels at serial determinations and without an alternative explanation; increased transaortic pressure gradient at stress echocardiography by > 20 mmHg; excessive LV hypertrophy without an alternative explanation
IIb
-
This indication is not covered in the AHA/ACC guidelines
Low-flow/low-gradient/low-LVEF severe AS without contractile/flow reserve
IIb
-
This indication is not covered in the AHA/ACC guidelines
Table 3 Suggested high-risk criteria in asymptomatic severe aortic stenosis
Test
High risk criteria
Electrocardiogram
Presence of LV hypertrophy with secondary ST segment deviation ("LV strain")
Blood tests
Highly increased BNP/Nt-ProBNP levels
Stress test
Unmasked symptoms: Fatigability/dyspnea at < 75 W, syncope/near syncope; angina
Lack of increase in systolic blood pressure by > 20 mmHg (or decrease) with exercise
Presence of severe valvular calcifications: Qualitatively (radiology, conventional echocardiography); quantitatively (computed tomography): Calcium score ≥ 1651 Agatston units (lower in women vs men)
Table 4 Criteria for the diagnosis of severe aortic regurgitation
Mild AR
Moderate AR
Severe AR
Ratio between the AR jet diameter and the LVOT diameter
< 25%
25%-64%
≥ 65%
Vena contracta (mm)
< 3
3-5.9
≥ 6
Regurgitant volume (mL/beat)
< 30
30-59
≥ 60
Regurgitant fraction
< 30%
30%-49%
≥ 50%
EROA (cm2)
< 0.1
0.1-0.29
≥ 0.3
Diastolic backflow in the descending thoracic and/or abdominal aorta
Minimal
Less than holodiastolic
Holodiastolic (especially for backflow documented in the abdominal aorta)
Angiographic
1+
2+
3-4+
LV dilatation
No
No
Yes (mandatory for chronic severe AR)
Table 5 Indications for aortic valve replacement in chronic aortic regurgitation[33,34]
Criteria
Class of indication
Differences between guidelines
ESC/EACTS
AHA/ACC
Symptomatic severe AR (any LVEF)
I
I
Asymptomatic severe AR with depressed LV function (LVEF < 50%)
I
I
Severe AR in patients with another indication for cardiac surgery (e.g., CABG, thoracic aorta, another valve)
I
I
Asymptomatic severe AR with normal LVEF (> 50%) but with severe LV dilatation
IIa
IIa
Definition of severe LV dilatation: ESC/EACTS guideline: End-diastolic LV diameter > 70 mm, or end-systolic LV diameter > 50 mm (or > 25 mm/m2); AHA/ACC guidelines: End-systolic LV diameter > 50 mm
Moderate AR in patients with another indication for cardiac surgery (e.g., coronary bypass, thoracic aorta, another valve)
-
IIa
This indication is not covered in the ESC/EACTS guidelines
Severe AR with normal LVEF (> 50%) but with progressive LV dilatation (end-diastolic LV diameter > 65 mm) if the surgical risk is low
-
IIb
This indication is not covered in the ESC/EACTS guidelines
Table 6 Indication for surgery in patients with bicuspid aortic valve and aortic root disease[33,34,66,67]
Class of indication
Guideline
Differences between guidelines
ESC/ EACTS 2012
AHA/ACC 2016 Consensus on AHA/ACC 2014, and ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM 2010 Guidelines
I
-
Asymptomatic bicuspid aortic valve with dilatation of Valsalva sinuses or the ascending thoracic aortic diameter > 55 mm
No class I indications in the 2012 ESC/EACTS guidelines
IIa
Bicuspid aortic valve with an ascending thoracic aortic diameter > 50 mm if the patient also has at least one of the followings: Family history of aortic dissection; documented increase in the aortic diameter > 2 mm/yr (assessed using the same imaging method, at the same level, and with comparative images available); arterial hypertension; coarctation of the aorta
Bicuspid aortic valve AND dilatation of the Valsalva sinuses or of the ascending thoracic aorta (> 50 mm) AND at least one of the following
Family history of aortic dissection
Documented increase in aortic diameter > 5 mm/yr
OR low surgical risk in an expert center
-
Replacement of the ascending aorta if the patient also has an indication for surgery for AS/AR, and the ascending aortic/Valsalva sinus diameter is > 45 mm
Not covered by the 2012 ESC guidelines
Citation: Mǎrgulescu AD. Assessment of aortic valve disease - a clinician oriented review. World J Cardiol 2017; 9(6): 481-495